Mehmet Bülent Vatan1, Perihan Varım1, Suret Ağaç2, Hakan Erkan3, Kahraman Coşansu1. 1. Sakarya University Training and Research Hospital, Department of Cardiology - Sakarya, Turkey. 2. Sakarya University Training and Research Hospital, Department of Biochemistry - Sakarya, Turkey. 3. University of Health Science Bursa City Hospital, Department of Cardiology - Bursa, Turkey.
Abstract
OBJECTIVE: This study aimed to evaluate the effects of statin response on cardiovascular outcomes in patients with ST-segment elevation myocardial infarction. METHODS: A total of 1029 ST-segment elevation myocardial infarction patients were enrolled in the study. The patients who failed to achieve >40% reduction in baseline low-density lipoprotein cholesterol levels within 30 days to 12 months after statin initiation were defined as suboptimal statin responders. The adjusted hazard ratios for cardiovascular outcomes for low-density lipoprotein cholesterol response to statins were estimated via the Cox proportional regression model. The relationship between the statin response and cardiovascular outcomes was also evaluated in a subgroup of on-treatment low-density lipoprotein cholesterol levels below 55 mg/dL. RESULTS: Among the study population, 573 (55.6%) patients demonstrated suboptimal low-density lipoprotein cholesterol response to statin therapy. These patients showed a significantly higher incidence of the composite of major adverse cardiovascular events, including cardiovascular death, reinfarction, recurrent myocardial infarction, and target vessel revascularization during the follow-up compared with optimal responders (adjusted hazard ratios 3.99; 95%CI 2.66-6.01; p<0.001). In a subgroup of patients with on-treatment low-density lipoprotein cholesterol levels below 55 mg/dL, suboptimal statin responders also showed unfavorable cardiovascular outcomes (adjusted hazard ratios 8.73; 95%CI 2.81-27.1; p<0.001). CONCLUSIONS: The present study showed that over half of the patients with ST-segment elevation myocardial infarction did not exhibit optimal low-density lipoprotein cholesterol response to statin. These patients have an increased risk of future major adverse cardiovascular events.
OBJECTIVE: This study aimed to evaluate the effects of statin response on cardiovascular outcomes in patients with ST-segment elevation myocardial infarction. METHODS: A total of 1029 ST-segment elevation myocardial infarction patients were enrolled in the study. The patients who failed to achieve >40% reduction in baseline low-density lipoprotein cholesterol levels within 30 days to 12 months after statin initiation were defined as suboptimal statin responders. The adjusted hazard ratios for cardiovascular outcomes for low-density lipoprotein cholesterol response to statins were estimated via the Cox proportional regression model. The relationship between the statin response and cardiovascular outcomes was also evaluated in a subgroup of on-treatment low-density lipoprotein cholesterol levels below 55 mg/dL. RESULTS: Among the study population, 573 (55.6%) patients demonstrated suboptimal low-density lipoprotein cholesterol response to statin therapy. These patients showed a significantly higher incidence of the composite of major adverse cardiovascular events, including cardiovascular death, reinfarction, recurrent myocardial infarction, and target vessel revascularization during the follow-up compared with optimal responders (adjusted hazard ratios 3.99; 95%CI 2.66-6.01; p<0.001). In a subgroup of patients with on-treatment low-density lipoprotein cholesterol levels below 55 mg/dL, suboptimal statin responders also showed unfavorable cardiovascular outcomes (adjusted hazard ratios 8.73; 95%CI 2.81-27.1; p<0.001). CONCLUSIONS: The present study showed that over half of the patients with ST-segment elevation myocardial infarction did not exhibit optimal low-density lipoprotein cholesterol response to statin. These patients have an increased risk of future major adverse cardiovascular events.
Authors: Jessica L Mega; David A Morrow; Alison Brown; Christopher P Cannon; Marc S Sabatine Journal: Arterioscler Thromb Vasc Biol Date: 2009-08-10 Impact factor: 8.311
Authors: Guy De Backer; Piotr Jankowski; Kornelia Kotseva; Erkin Mirrakhimov; Željko Reiner; Lars Rydén; Lale Tokgözoğlu; David Wood; Dirk De Bacquer Journal: Atherosclerosis Date: 2019-04-24 Impact factor: 5.162
Authors: Akinyemi Oni-Orisan; Thomas J Hoffmann; Dilrini Ranatunga; Marisa W Medina; Eric Jorgenson; Catherine Schaefer; Ronald M Krauss; Carlos Iribarren; Neil Risch Journal: Circ Genom Precis Med Date: 2018-09
Authors: Joel A Simon; Feng Lin; Stephen B Hulley; Patricia J Blanche; David Waters; Stephen Shiboski; Jerome I Rotter; Deborah A Nickerson; Huiying Yang; Mohammed Saad; Ronald M Krauss Journal: Am J Cardiol Date: 2006-01-27 Impact factor: 2.778
Authors: Sripal Bangalore; Rana Fayyad; John J Kastelein; Rachel Laskey; Pierre Amarenco; David A DeMicco; David D Waters Journal: Am J Med Date: 2015-11-06 Impact factor: 4.965
Authors: François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund Journal: Eur Heart J Date: 2020-01-01 Impact factor: 29.983
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321